We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
Analysts on Wall Street project that Abbott (ABT - Free Report) will announce quarterly earnings of $1.42 per share in its forthcoming report, representing an increase of 9.2% year over year. Revenues are projected to reach $12.97 billion, increasing 14.1% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Abbott metrics that are commonly monitored and projected by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net sales- Nutrition' of $2.21 billion. The estimate suggests a change of +2.7% year over year.
Analysts' assessment points toward 'Net sales- Diagnostics' reaching $3.29 billion. The estimate indicates a year-over-year change of +45.9%.
Based on the collective assessment of analysts, 'Net sales- Medical Devices- Diabetes Care' should arrive at $2.20 billion. The estimate indicates a year-over-year change of +6.8%.
According to the collective judgment of analysts, 'Net sales- Established Pharmaceuticals' should come in at $1.61 billion. The estimate points to a change of +6.8% from the year-ago quarter.
Analysts predict that the 'Net sales- Nutrition- U.S.' will reach $931.65 million. The estimate indicates a change of +4.9% from the prior-year quarter.
It is projected by analysts that the 'Net sales- Nutrition- International' will reach $1.28 billion. The estimate suggests a change of +1.3% year over year.
The combined assessment of analysts suggests that 'Net sales- Diagnostics- U.S.' will likely reach $1.85 billion. The estimate indicates a change of +108.3% from the prior-year quarter.
The consensus among analysts is that 'Net sales- Diagnostics- International' will reach $1.44 billion. The estimate suggests a change of +5.7% year over year.
Analysts expect 'Net sales- Medical Devices- Neuromodulation- International' to come in at $63.91 million. The estimate indicates a year-over-year change of +10.2%.
The average prediction of analysts places 'Net sales- Medical Devices- Rhythm Management- U.S.' at $388.69 million. The estimate indicates a year-over-year change of +11.1%.
The consensus estimate for 'Net sales- Medical Devices- Rhythm Management- International' stands at $350.76 million. The estimate indicates a change of +4.4% from the prior-year quarter.
Analysts forecast 'Net sales- Medical Devices- Structural Heart- U.S.' to reach $245.18 million. The estimate indicates a change of -17.5% from the prior-year quarter.
Abbott shares have witnessed a change of +2.4% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #2 (Buy), ABT is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Analysts on Wall Street project that Abbott (ABT - Free Report) will announce quarterly earnings of $1.42 per share in its forthcoming report, representing an increase of 9.2% year over year. Revenues are projected to reach $12.97 billion, increasing 14.1% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Abbott metrics that are commonly monitored and projected by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net sales- Nutrition' of $2.21 billion. The estimate suggests a change of +2.7% year over year.
Analysts' assessment points toward 'Net sales- Diagnostics' reaching $3.29 billion. The estimate indicates a year-over-year change of +45.9%.
Based on the collective assessment of analysts, 'Net sales- Medical Devices- Diabetes Care' should arrive at $2.20 billion. The estimate indicates a year-over-year change of +6.8%.
According to the collective judgment of analysts, 'Net sales- Established Pharmaceuticals' should come in at $1.61 billion. The estimate points to a change of +6.8% from the year-ago quarter.
Analysts predict that the 'Net sales- Nutrition- U.S.' will reach $931.65 million. The estimate indicates a change of +4.9% from the prior-year quarter.
It is projected by analysts that the 'Net sales- Nutrition- International' will reach $1.28 billion. The estimate suggests a change of +1.3% year over year.
The combined assessment of analysts suggests that 'Net sales- Diagnostics- U.S.' will likely reach $1.85 billion. The estimate indicates a change of +108.3% from the prior-year quarter.
The consensus among analysts is that 'Net sales- Diagnostics- International' will reach $1.44 billion. The estimate suggests a change of +5.7% year over year.
Analysts expect 'Net sales- Medical Devices- Neuromodulation- International' to come in at $63.91 million. The estimate indicates a year-over-year change of +10.2%.
The average prediction of analysts places 'Net sales- Medical Devices- Rhythm Management- U.S.' at $388.69 million. The estimate indicates a year-over-year change of +11.1%.
The consensus estimate for 'Net sales- Medical Devices- Rhythm Management- International' stands at $350.76 million. The estimate indicates a change of +4.4% from the prior-year quarter.
Analysts forecast 'Net sales- Medical Devices- Structural Heart- U.S.' to reach $245.18 million. The estimate indicates a change of -17.5% from the prior-year quarter.
View all Key Company Metrics for Abbott here>>>Abbott shares have witnessed a change of +2.4% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #2 (Buy), ABT is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .